300199.SHE Hybio Pharmaceutical
- Market cap
- CNY 19.2B
- P/E
- 48.3x
- P/B
- 18.02x
- ROE
- 54.3%
- Dividend yield
- 0.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300199.SHE undervalued?
Graham numberThe Graham number of Hybio Pharmaceutical cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hybio Pharmaceutical fundamental analysis
No fundamental analysis for Hybio Pharmaceutical yet.
Hybio Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical products in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as medical devices comprising disposable injectable pens; and peptide active pharmaceutical ingr…
Full company profileHybio Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hybio Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 855M | 1.25B | 1.26B | 614M | 722M | 736M | 704M | 431M | 590M | 966M | 1.66B |
| Gross Profit | 685M | 1.05B | 1.08B | 480M | 568M | 464M | 509M | 171M | 309M | 564M | 1.07B |
| Operating Income | 278M | 354M | -320M | -905M | -574M | 39.1M | -371M | -508M | -161M | 219M | 669M |
| EBITDA | 442M | 476M | 308M | -393M | -441M | -145M | -52.6M | -223M | 114M | 295M | 696M |
| Net Income | 292M | 330M | -341M | -885M | -609M | 30.8M | -371M | -514M | -174M | 36.6M | 582M |
| EPS | 0.33 | 0.35 | -0.37 | -1.00 | -0.69 | 0.03 | -0.42 | -0.58 | -0.20 | 0.04 | 0.66 |
| Balance Sheet | |||||||||||
| Total Assets | 4.46B | 5.30B | 5.66B | 4.72B | 4.04B | 3.91B | 3.61B | 3.28B | 3.01B | 3.15B | 3.95B |
| Total Liabilities | 852M | 1.41B | 2.27B | 2.49B | 2.36B | 2.26B | 2.31B | 2.49B | 2.41B | 2.52B | 2.86B |
| Shareholders' Equity | 3.60B | 3.88B | 3.39B | 2.23B | 1.64B | 1.58B | 1.27B | 759M | 579M | 614M | 1.07B |
| Cash & Short-term Investments | 881M | 1.27B | 1.56B | 821M | 452M | 617M | 267M | 344M | 96.0M | 101M | 206M |
| Total Debt | 418M | 775M | 1.76B | 1.91B | 1.74B | 1.71B | 1.34B | 1.56B | 1.50B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 296M | 229M | 47.0M | 105M | 48.0M | 157M | 15.8M | -3.54M | 165M | 234M | - |
| Capital Expenditure | 116M | 221M | 366M | 570M | 244M | 199M | 190M | 81.8M | 116M | 234M | 354M |
| Free Cash Flow | 180M | -7.39M | -319M | -466M | -196M | -42.2M | -174M | -85.3M | 48.9M | -450K | 151M |
| Ratios | |||||||||||
| ROE | 8.1% | 8.5% | -10.0% | -39.7% | -37.2% | 1.9% | -29.2% | -67.7% | -30.0% | 6.0% | 54.3% |
| ROA | 6.5% | 6.2% | -6.0% | -18.7% | -15.1% | 0.8% | -10.3% | -15.7% | -5.8% | 1.2% | 14.8% |
| Net Profit Margin | 34.1% | 26.5% | -27.0% | -144.1% | -84.4% | 4.2% | -52.6% | -119.1% | -29.4% | 3.8% | 35.1% |
| Debt to Equity | 0.12x | 0.20x | 0.52x | 0.86x | 1.06x | 1.08x | 1.05x | 2.05x | 2.59x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hybio Pharmaceutical dividends
- Dividend yield
- 0.49%
- Forward dividend
- -
- Payout ratio
- 259.3%
- Ex-dividend date
- Apr 19, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 94.8M | 0.11 | 259.3% |
| 2024 | CNY 112M | 0.13 | - |
| 2023 | CNY 118M | 0.13 | - |
| 2022 | CNY 115M | 0.13 | - |
| 2021 | CNY 116M | 0.13 | 375.4% |
| 2020 | CNY 105M | 0.12 | - |
| 2019 | CNY 115M | 0.13 | - |
| 2018 | CNY 253M | 0.27 | - |
| 2017 | CNY 128M | 0.14 | 38.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Apr 14, 2015.
Who owns Hybio Pharmaceutical
- Insiders 23.62%
- Institutions 1.75%
- Public & others 74.63%
- Shares outstanding 883M
- Free float 652M
Hybio Pharmaceutical company profile
- Company name
- Hybio Pharmaceutical
- Ticker
- 300199.SHE
- ISIN
- CNE1000011T7
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 7, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,226
- Fiscal year end
- December
- Address
- Hanyu Innovation Industry Building, Wuhan, China, 518110
- Phone
- 86 755 2658 8036
- Website
- hybio.com.cn
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical products in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as medical devices comprising disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; mental and behavioral disorders; tumor; urogenital system diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. In addition, the company engages in the provision of property services, technical services, technology development, technical consulting, technical exchange, technology transfer, and technology promotion, as well as non-residential real estate leasing. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Wuhan, China.
Hybio Pharmaceutical management
8- Mr. Shaogui ZengPresident, Chairman & Secretary · born 1968
- Mr. Honghong TuVP & CFO · born 1976
- Ms. Min ZhangVice President of HR, Corporate Management & Administrative Department · born 1980
- Mr. Yangming TangVP & Director · born 1978
- Mr. Ya Ping ShenExecutive President & Director · born 1962
- Mr. Baole ZhangVice President · born 1987
- Caiyun BianAccounting Supervisor
- Mr. Yu LiuVice President of Marketing